{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:09:28Z","timestamp":1782364168386,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"The local agents of rituximab provided the study medications, some laboratory reagents and a study coordinator. The local agents of leflunomide provided study medications and matching placebo tablets","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12891-017-1673-3","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T09:15:51Z","timestamp":1500455751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Harindu","family":"Wijesinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadharshini","family":"Galappatthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiva","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suranjith L.","family":"Seneviratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ushagowry","family":"Saravanamuttu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Udagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upul","family":"Senerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Fernandopulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilani P.","family":"Weerasekera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalith S.","family":"Wijayaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"issue":"6","key":"1673_CR1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762\u201384.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1673_CR2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625\u201339.","journal-title":"Arthritis Care Res"},{"key":"1673_CR3","unstructured":"Administration USFDA Drug Safety Communication: new boxed warning for severe liver injury with arthritis drug Arava (leflunomide). 2010. \nwww.fda.gov\/Drugs\/DrugSafety\/ucm218679.html\n\n (accessed 15 May 2015)."},{"issue":"9688","key":"1673_CR4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","volume":"374","author":"RF Vollenhoven van","year":"2009","unstructured":"van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374(9688):459\u201366.","journal-title":"Lancet"},{"issue":"11","key":"1673_CR5","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"EW St. Clair","year":"2004","unstructured":"St. Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432\u201343.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1673_CR6","first-page":"706","volume":"34","author":"S-S Seong","year":"2007","unstructured":"Seong S-S, Choi C-B, Woo J-H, Bae KW, Joung C-L, Uhm W-S, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34(4):706\u201311.","journal-title":"J Rheumatol"},{"issue":"Supplement 3","key":"1673_CR7","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","volume":"41","author":"RS Wallis","year":"2005","unstructured":"Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005;41(Supplement 3):S194\u2013S8.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1673_CR8","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","volume":"44","author":"J Keane","year":"2005","unstructured":"Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology. 2005;44(6):714\u201320.","journal-title":"Rheumatology"},{"issue":"7","key":"1673_CR9","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Br\u00e9ban M, et al. Risk of tuberculosis is higher with anti\u2013tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60(7):1884\u201394.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1673_CR10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/ken103","volume":"47","author":"D McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Madden J, Taylor L, Emery P. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47(6):865\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1673_CR11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"90","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Burmester G, Darner T, Ferraccioli G. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;90(6):909\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"1673_CR12","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572\u201381.","journal-title":"N Engl J Med"},{"issue":"9","key":"1673_CR13","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793\u2013806.","journal-title":"Arthritis Rheum"},{"key":"1673_CR14","doi-asserted-by":"publisher","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2012; doi:\n10.1136\/annrheumdis-2012-201956\n\n.","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"1673_CR15","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","volume":"49","author":"A Rubbert-Roth","year":"2010","unstructured":"Rubbert-Roth A, Tak PP, Zerbini C, Tremblay J-L, Carre\u00f1o L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology. 2010;49:1683\u201393.","journal-title":"Rheumatology"},{"issue":"5","key":"1673_CR16","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390\u2013400.","journal-title":"Arthritis Rheum"},{"key":"1673_CR17","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepa\u0144ski LJ, Roschmann RA, Chen A. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (study evaluating Rituximab's efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629\u201335.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"1673_CR18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/acr.22116","volume":"66","author":"M Bredemeier","year":"2014","unstructured":"Bredemeier M, Oliveira FK, Rocha CM. Low-versus high-dose Rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2014 Feb 1;66(2):228\u201335.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1673_CR19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13075-016-0951-z","volume":"18","author":"K Chatzidionysiou","year":"2016","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordstr\u00f6m DC, Gabay C, Canh\u00e3o H. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016 Feb 16;18(1):50.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"1673_CR20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-137-9-200211050-00007","volume":"137","author":"JM Kremer","year":"2002","unstructured":"Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(9):726\u201333.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1673_CR21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200427050-00006","volume":"27","author":"EN Roon van","year":"2004","unstructured":"van Roon EN, Tim LTA, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheumatoid arthritis in clinical practice. Drug Saf. 2004;27(5):345\u201352.","journal-title":"Drug Saf"},{"issue":"3","key":"1673_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3899\/jrheum.120922","volume":"40","author":"P Bird","year":"2013","unstructured":"Bird P, Griffiths H, Tymms K, Nicholls D, Roberts L, Arnold M, Burnet S, de Jager J, Scott J, Zochling J, Littlejohn G. The SMILE study\u2014safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol. 2013 Mar 1;40(3):228\u201335.","journal-title":"J Rheumatol"},{"issue":"3","key":"1673_CR23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar 1;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"key":"1673_CR24","doi-asserted-by":"crossref","unstructured":"Rheumatoid arthritis: No advantage of leflunomide loading dose. Nat Rev Rheumatol. 2013;9(4):196.","DOI":"10.1038\/nrrheum.2013.35"},{"key":"1673_CR25","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2012;72:1\u20137."},{"issue":"12","key":"1673_CR26","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3899\/jrheum.120573","volume":"39","author":"EC Keystone","year":"2012","unstructured":"Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol. 2012;39(12):2238\u201346.","journal-title":"J Rheumatol"},{"issue":"1","key":"1673_CR27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","volume":"71","author":"A Mekinian","year":"2012","unstructured":"Mekinian A, Ravaud P, Hatron P, Larroche C, Leone J, Gombert B, et al. Efficacy of rituximab in primary Sj\u00f6gren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1673_CR28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.120924","volume":"40","author":"WFC Rigby","year":"2013","unstructured":"Rigby WFC, Mease PJ, Olech E, Ashby M, Tole S. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study. J Rheumatol. 2013;40(5):599\u2013604.","journal-title":"J Rheumatol"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-017-1673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T09:16:09Z","timestamp":1500455769000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-017-1673-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1186\/s12891-017-1673-3","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]},"article-number":"310"}}